{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:39:55Z","timestamp":1794674395327,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Foundation Grants","award":["RS-2022-NR069839"],"award-info":[{"award-number":["RS-2022-NR069839"]}]},{"name":"National Research Foundation Grants","award":["RS-2024-00352915"],"award-info":[{"award-number":["RS-2024-00352915"]}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-02283199"],"award-info":[{"award-number":["RS-2025-02283199"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer is a highly lethal malignancy with limited treatment response. Despite advancements in treatment, systemic chemotherapy remains the primary therapeutic approach for over 80% of patients, with no established biomarkers to guide drug selection. Traditional two-dimensional (2D) culture models fail to replicate the tumor microenvironment, necessitating the development of more advanced models, such as three-dimensional (3D) organoid models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established 3D organoid cultures using patient-derived conditionally reprogrammed cell (CRC) lines, originally cultured under 2D conditions. These CRC organoids were developed using a Matrigel-based platform without organoid-specific medium components to preserve the intrinsic molecular subtypes of the cells. Morphological, molecular, and drug sensitivity analyses were performed to compare the clinical responses of 3D CRC organoids with those of their 2D counterparts and clinical responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 3D CRC organoids retained the molecular characteristics, transcriptomic and mutational profiles of the parental tumors and displayed distinct morphologies corresponding to cancer stages and differentiation. Drug response profiling of gemcitabine plus nab-paclitaxel (Abraxane) and FOLFIRINOX demonstrated that the 3D organoids more accurately mirrored patient clinical responses than the 2D cultures. Notably, the IC50 values for the 3D organoids were generally higher, reflecting the structural complexity and drug penetration barriers observed in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Matrigel-based 3D organoid culture models provide a robust platform for pre-clinical drug evaluation, overcoming the limitations of 2D models. Although time- and resource-intensive, integrating both 2D and 3D platforms enables efficient initial screening and validation. This approach holds promise for identifying predictive biomarkers and advancing precision medicine in pancreatic cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02374-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:07:20Z","timestamp":1748909240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Jin Su","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghee","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Jae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Youp","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galam","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2374_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2374_CR2","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US Cancer incidence and death to 2040. JAMA Netw Open. 2021;4:e214708.","journal-title":"JAMA Netw Open"},{"key":"2374_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch A-M, Wu J, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399\u2013405.","journal-title":"Nature"},{"key":"2374_CR4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801\u20136.","journal-title":"Science"},{"key":"2374_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"H-f Hu","year":"2021","unstructured":"Hu H-f, Ye Z, Qin Y, Xu X-w, Yu X-j. Zhuo Q-f, Ji S-r: mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin. 2021;42:1725\u201341.","journal-title":"Acta Pharmacol Sin"},{"key":"2374_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, Fouchardi\u00e8re C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic Cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"2374_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic Cancer with nab-Paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"2374_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"2374_CR9","first-page":"910","volume":"14","author":"M Kapalczynska","year":"2018","unstructured":"Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V, Ibbs M, Blizniak R, Luczewski L, Lamperska K. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14:910\u20139.","journal-title":"Arch Med Sci"},{"key":"2374_CR10","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1242\/jcs.054551","volume":"122","author":"H Mizushima","year":"2009","unstructured":"Mizushima H, Wang X, Miyamoto S, Mekada E. Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures. J Cell Sci. 2009;122:4277\u201386.","journal-title":"J Cell Sci"},{"key":"2374_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.biomaterials.2015.07.003","volume":"65","author":"GS Huang","year":"2015","unstructured":"Huang GS, Tseng TC, Dai NT, Fu KY, Dai LG, Hsu SH. Fast isolation and expansion of multipotent cells from adipose tissue based on chitosan-selected primary culture. Biomaterials. 2015;65:154\u201362.","journal-title":"Biomaterials"},{"key":"2374_CR12","doi-asserted-by":"publisher","first-page":"18380","DOI":"10.1038\/s41598-023-45144-w","volume":"13","author":"ZN Abbas","year":"2023","unstructured":"Abbas ZN, Al-Saffar AZ, Jasim SM, Sulaiman GM. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. Sci Rep. 2023;13:18380.","journal-title":"Sci Rep"},{"key":"2374_CR13","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1038\/s41598-019-47416-w","volume":"9","author":"Y Shichi","year":"2019","unstructured":"Shichi Y, Sasaki N, Michishita M, Hasegawa F, Matsuda Y, Arai T, Gomi F, Aida J, Takubo K, Toyoda M, et al. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Sci Rep. 2019;9:10871.","journal-title":"Sci Rep"},{"key":"2374_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2121-14-43","volume":"14","author":"K Lawrenson","year":"2013","unstructured":"Lawrenson K, Notaridou M, Lee N, Benjamin E, Jacobs IJ, Jones C, Gayther SA. In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol. 2013;14:43.","journal-title":"BMC Cell Biol"},{"key":"2374_CR15","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125.","journal-title":"Science"},{"key":"2374_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cell.2014.08.017","volume":"159","author":"WR Karthaus","year":"2014","unstructured":"Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014;159:163\u201375.","journal-title":"Cell"},{"key":"2374_CR17","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1002\/cam4.2210","volume":"8","author":"HS Lee","year":"2019","unstructured":"Lee HS, Lee JS, Lee J, Kim EK, Kim H, Chung MJ, Park JY, Park SW, Song SY, Bang S. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Cancer Med. 2019;8:3339\u201348.","journal-title":"Cancer Med"},{"key":"2374_CR18","doi-asserted-by":"publisher","first-page":"103218","DOI":"10.1016\/j.ebiom.2021.103218","volume":"65","author":"HS Lee","year":"2021","unstructured":"Lee HS, Kim E, Lee J, Park SJ, Hwang HK, Park CH, Jo SY, Kang CM, Hong SM, Kang H, et al. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine. 2021;65:103218.","journal-title":"EBioMedicine"},{"key":"2374_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/0008-5472.CAN-22-2045","volume":"83","author":"SJ Park","year":"2023","unstructured":"Park SJ, Yoo HC, Ahn E, Luo E, Kim Y, Sung Y, Yu YC, Kim K, Min DS, Lee HS, et al. Enhanced Glutaminolysis drives Hypoxia-Induced chemoresistance in pancreatic Cancer. Cancer Res. 2023;83:735\u201352.","journal-title":"Cancer Res"},{"key":"2374_CR20","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1096\/fj.202000363RR","volume":"34","author":"N Juiz","year":"2020","unstructured":"Juiz N, Elkaoutari A, Bigonnet M, Gayet O, Roques J, Nicolle R, Iovanna J, Dusetti N. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype. FASEB J. 2020;34:12214\u201328.","journal-title":"FASEB J"},{"key":"2374_CR21","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1158\/0008-5472.CAN-12-4384","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Morris JP, Yan IV, Schofield W, Gurney HK, Simeone A, Millar DM, Hoey SE, Hebrok T. Pasca Di Magliano M: canonical Wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013;73:4909\u201322.","journal-title":"Cancer Res"},{"key":"2374_CR22","doi-asserted-by":"publisher","first-page":"e0298808","DOI":"10.1371\/journal.pone.0298808","volume":"19","author":"HJ Hawkins","year":"2024","unstructured":"Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, et al. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). PLoS ONE. 2024;19:e0298808.","journal-title":"PLoS ONE"},{"key":"2374_CR23","doi-asserted-by":"crossref","unstructured":"Aguilera KY, Dawson DW. WNT ligand dependencies in pancreatic Cancer. Front Cell Dev Biology 2021, 9.","DOI":"10.3389\/fcell.2021.671022"},{"key":"2374_CR24","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.3390\/ijms20174242","volume":"20","author":"M Ram Makena","year":"2019","unstructured":"Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, Pandey K, Pramanik MC. Wnt\/\u03b2-Catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Int J Mol Sci. 2019;20:4242.","journal-title":"Int J Mol Sci"},{"key":"2374_CR25","doi-asserted-by":"crossref","unstructured":"Sprangers J, Bugter JM, Xanthakis D, Boekhout M, Kok RNU, Brosens LAA, Dijk F, Rodriguez Colman MJ, van der Vaart JY, Maurice MM. WNT7B drives a program for pancreatic cancer subtype switching and progression. bioRxiv 2024:2024.2012.2018.628910.","DOI":"10.1101\/2024.12.18.628910"},{"key":"2374_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/term.3248","volume":"15","author":"SW Zhang","year":"2021","unstructured":"Zhang SW, Chen W, Lu XF, Wen Z, Hu L, Liu YH, Yang Z, Xue L, Su Q, Yan LP, et al. An efficient and user-friendly method for cytohistological analysis of organoids. J Tissue Eng Regen Med. 2021;15:1012\u201322.","journal-title":"J Tissue Eng Regen Med"},{"key":"2374_CR27","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.xpro.2020.100041","volume":"1","author":"P Worsdorfer","year":"2020","unstructured":"Worsdorfer P, Rockel A, Alt Y, Kern A, Ergun S. Generation of vascularized neural organoids by Co-culturing with mesodermal progenitor cells. STAR Protoc. 2020;1:100041.","journal-title":"STAR Protoc"},{"key":"2374_CR28","doi-asserted-by":"publisher","first-page":"582218","DOI":"10.3389\/fnana.2020.582218","volume":"14","author":"S Zaqout","year":"2020","unstructured":"Zaqout S, Becker LL, Kaindl AM. Immunofluorescence staining of paraffin sections step by step. Front Neuroanat. 2020;14:582218.","journal-title":"Front Neuroanat"},{"key":"2374_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4132\/KoreanJPathol.2014.48.5.351","volume":"48","author":"SJ Choi","year":"2014","unstructured":"Choi SJ, Choi YI, Kim L, Park IS, Han JY, Kim JM, Chu YC. Preparation of compact agarose cell blocks from the residues of liquid-based cytology samples. Korean J Pathol. 2014;48:351\u201360.","journal-title":"Korean J Pathol"},{"key":"2374_CR30","doi-asserted-by":"publisher","first-page":"100239","DOI":"10.1016\/j.xpro.2020.100239","volume":"2","author":"Z Li","year":"2021","unstructured":"Li Z, Yu L, Chen D, Meng Z, Chen W, Huang W. Protocol for generation of lung adenocarcinoma organoids from clinical samples. STAR Protoc. 2021;2:100239.","journal-title":"STAR Protoc"},{"key":"2374_CR31","doi-asserted-by":"crossref","unstructured":"Martin M. CUTADAPT removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 2011, 17.","DOI":"10.14806\/ej.17.1.200"},{"key":"2374_CR32","doi-asserted-by":"crossref","unstructured":"Porter RL, Magnus NKC, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences 2019, 116:26835\u201326845.","DOI":"10.1073\/pnas.1914915116"},{"key":"2374_CR33","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo B-K, Huch M. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11:1724\u201343.","journal-title":"Nat Protoc"},{"key":"2374_CR34","doi-asserted-by":"publisher","first-page":"100192","DOI":"10.1016\/j.xpro.2020.100192","volume":"1","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Gracanin A, Vries RGJ, Clevers H, Boj SF. Establishment of pancreatic organoids from normal tissue and tumors. STAR Protoc. 2020;1:100192.","journal-title":"STAR Protoc"},{"key":"2374_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-024-02216-3","volume":"24","author":"Y Shi","year":"2025","unstructured":"Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M, Cao B. Targeting KRAS: from metabolic regulation to cancer treatment. Mol Cancer. 2025;24:9.","journal-title":"Mol Cancer"},{"key":"2374_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Ma Q, Zhang W, Wu K, Shi L. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24:14.","journal-title":"Mol Cancer"},{"key":"2374_CR37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Therapy. 2021;6:386.","journal-title":"Signal Transduct Target Therapy"},{"key":"2374_CR38","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang H, Liao X, Tsai H-i. KRAS mutation: the booster of pancreatic ductal adenocarcinoma transformation and progression. Front Cell Dev Biology 2023, Volume 11\u20132023.","DOI":"10.3389\/fcell.2023.1147676"},{"key":"2374_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","volume":"10","author":"Y Lai","year":"2017","unstructured":"Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10:106.","journal-title":"J Hematol Oncol"},{"key":"2374_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12967-020-02414-9","volume":"18","author":"Z Liu","year":"2020","unstructured":"Liu Z, Ahn MH, Kurokawa T, Ly A, Zhang G, Wang F, Yamada T, Sadagopan A, Cheng J, Ferrone CR, et al. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. J Transl Med. 2020;18:255.","journal-title":"J Transl Med"},{"key":"2374_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3389\/fonc.2020.00843","volume":"10","author":"RM Brock","year":"2020","unstructured":"Brock RM, Beitel-White N, Coutermarsh-Ott S, Grider DJ, Lorenzo MF, Ringel-Scaia VM, Manuchehrabadi N, Martin RCG, Davalos RV, Allen IC. Patient derived xenografts expand human primary pancreatic tumor tissue availability for ex vivo irreversible electroporation testing. Front Oncol. 2020;10:843.","journal-title":"Front Oncol"},{"key":"2374_CR42","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.1038\/s41598-021-90049-1","volume":"11","author":"NA Pham","year":"2021","unstructured":"Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, Weiss J, Raghavan V, Cabanero M, Denroche RE, et al. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep. 2021;11:10619.","journal-title":"Sci Rep"},{"key":"2374_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u20133.","journal-title":"Nat Med"},{"key":"2374_CR44","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168\u201378.","journal-title":"Nat Genet"},{"key":"2374_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, Miller DK, Christ AN, Bruxner TJC, Quinn MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.","journal-title":"Nature"},{"key":"2374_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Reviews Gastroenterol Hepatol. 2019;16:207\u201320.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"2374_CR47","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"2374_CR48","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Gr\u00fcnwald BT, Jang G-H, Masoomian M, Picardo S, Grant RC, Denroche RE, Zhang A, Wang Y, Miller JK, et al. GATA6 expression distinguishes classical and Basal-like subtypes in advanced pancreatic Cancer. Clin Cancer Res. 2020;26:4901\u201310.","journal-title":"Clin Cancer Res"},{"key":"2374_CR49","doi-asserted-by":"publisher","first-page":"5826","DOI":"10.1038\/s41467-021-26059-4","volume":"12","author":"TG Krieger","year":"2021","unstructured":"Krieger TG, Le Blanc S, Jabs J, Ten FW, Ishaque N, Jechow K, Debnath O, Leonhardt CS, Giri A, Eils R, et al. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun. 2021;12:5826.","journal-title":"Nat Commun"},{"key":"2374_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","volume":"41","author":"S Schuth","year":"2022","unstructured":"Schuth S, Le Blanc S, Krieger TG, Jabs J, Schenk M, Giese NA, Buchler MW, Eils R, Conrad C, Strobel O. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022;41:312.","journal-title":"J Exp Clin Cancer Res"},{"key":"2374_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-022-02301-9","volume":"41","author":"T Shinkawa","year":"2022","unstructured":"Shinkawa T, Ohuchida K, Mochida Y, Sakihama K, Iwamoto C, Abe T, Ideno N, Mizuuchi Y, Shindo K, Ikenaga N, et al. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. J Exp Clin Cancer Res. 2022;41:89.","journal-title":"J Exp Clin Cancer Res"},{"key":"2374_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-024-01287-7","volume":"16","author":"S Kim","year":"2024","unstructured":"Kim S, Leem G, Choi J, Koh Y, Lee S, Nam S-H, Kim JS, Park CH, Hwang HK, Min KI, et al. Integrative analysis of Spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis. Genome Med. 2024;16:20.","journal-title":"Genome Med"},{"key":"2374_CR53","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"22","author":"T Seino","year":"2018","unstructured":"Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018;22:454\u2013e467456.","journal-title":"Cell Stem Cell"},{"key":"2374_CR54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang G-H, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic Cancer. Cancer Discov. 2018;8:1112\u201329.","journal-title":"Cancer Discov"},{"key":"2374_CR55","doi-asserted-by":"publisher","first-page":"103539","DOI":"10.1016\/j.xpro.2024.103539","volume":"6","author":"K Takeuchi","year":"2025","unstructured":"Takeuchi K, Tabe S, Yamamoto Y, Takahashi K, Matsuo M, Ueno Y, Ohtsuka M, Morinaga S, Miyagi Y, Yamaguchi T, et al. Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. STAR Protocols. 2025;6:103539.","journal-title":"STAR Protocols"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02374-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02374-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02374-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:04:04Z","timestamp":1748912644000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02374-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2374"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02374-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5823082\/v1","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Yonsei University Medical Center (number 4-2019-0614).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}